Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu PODXL Purified

Anti-Hu PODXL Purified

Regulatory status

RUO

Antigen

PODXL

Clone

PcMab-47

Format

Purified

Reactivity

Human

Application

IHC, WB, FC (QC tested)

Variant

0.1 mg

11-899-C100

In stock

154.00 USD

Variant

0.1 mg

11-899-C100

In stock

154.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1 kappa

Specificity

The mouse monoclonal antibody PcMab-47 recognizes a glycosylation-dependent epitope (aa 207-210) on human PODXL, a highly glycosylated transmembrane glycoprotein expressed above all in many types of cancer tissues, and on embryonic stem cells.

Application

IHC, WB, FC (QC tested)

Application details

Flow cytometry: Recommended dilution: 1-4 μg/ml.

Reactivity

Human

Immunogen

recombinant PODXL ectodomain

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

PCLP-1, Gp200, podocalyxin like

Antigen description

PODXL is a highly glycosylated sialomucin, which is expressed in many types of tumors, as well as it is a well known marker of embryonic stem cells. Overexpression of PODXL is an independent predictor of cancer progression, metastasis, and poor outcome. PODXL promotes tumor growts and invasiveness, and is a potential target for antibody therapy.

Entrez Gene ID 5420

UniProt ID O00592

Separation of HeLa cells stained anti-human PODXL (PcMab-47) purified antibody (concentration in sample 1,7 μg/ml, GAM APC, red-filled) from HeLa cells unstained by primary antibody (GAM APC, black-dashed) in flow cytometry analysis (surface staining).

Product specific references:

Schulten HJ, Hussein D: Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas. PLoS One 2019 May 13;14(5):e0215452.
PubMed

Itai S, Yamada S, Kaneko MK, Kato Y: Determination of critical epitope of PcMab-47 against human podocalyxin. Biochem Biophys Rep. 2018 Apr 24;14:78-82.
PubMed

Ogasawara S, Kaneko MK, Yamada S, Honma R, Nakamura T, Saidoh N, Yanaka M, Yoshida K, Fujii Y, Kato Y: PcMab-47: Novel antihuman podocalyxin monoclonal antibody for immunohistochemistry. Monoclon Antib Immunodiagn Immunother. 2017 Apr;36(2):50-56.
PubMed

Itai S, Ohishi T, Kaneko MK, Yamada S, Abe S, Nakamura T, Yanaka M, Chang YW, Ohba SI, Nishioka Y, Kawada M, Harada H, Kato Y: Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. Oncotarget 2018 Apr 27;9(32):22480-22497.
PubMed

Kaneko MK, Ohishi T, Kawada M, Kato Y: A cancer-specific anti-podocalyxin monoclonal antibody (60-mG 2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma. Biochem Biophys Rep. 2020 Oct 10;24:100826.
PubMed